2 results
Approved WMOCompleted
The primary objective of this study is to demonstrate the impact on time in hypoglycaemia (number of hours per day of hypoglycaemic excursions < 3.9 mmol/L, 70 mg/dL) using the Abbott Sensor Based Glucose Monitoring System compared to Self…
Approved WMOCompleted
Lu AF28996 is an orally administered investigational compound of a potent, long-acting dopamine agonist, Lu AA40326, currently under development by H. Lundbeck A/S for the treatment of Parkinson*s disease (PD). Primary Objective:to investigate the…